Novel Antimicrobials Hailed as a 'Turning Point' in Combating Antibiotic-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to health experts.
A Global Public Health Issue
Gonorrhoea infections are increasing globally, with figures suggesting over 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.
“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”
Health officials are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.
Recent Treatment Options Receive Clearance
One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.
Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.
A Novel Development Model
Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.
“This milestone marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”
Research Study Results and Worldwide Availability
As per data detailed in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an comparable level with the typical regimen, which involves two antibiotics. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.
Under the terms of its unique model, the non-profit has the authority to license and sell the drug in a wide range of developing nations.
Doctors directly involved have shared optimism. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.
